Preventing autoimmunity protects against the development of hypertension and renal injury

Pharmacology, Toxicology and Pharmaceutical Science

• Systemic Lupus Erythematosus 100%
• Autoantibodies 100%
• Kidney Injury 100%
• Cytokine 50%
• Mouse Model 50%
• Fibrosis 50%
• Double Stranded DNA 50%
• Prevalence 50%
• Disease Exacerbation 50%
• Essential Hypertension 50%
• Autoimmune Disease 50%
• Tumor Necrosis Factor 50%
• Nephritis 50%
• Glomerulosclerosis 50%
• Immunoglobulin G Antibody 50%
• Neutrophil Gelatinase Associated Lipocalin 50%
• New Zealand White Mouse 50%
• CD20 Antibody 50%
• Monocyte Chemotactic Protein 1 50%
• Albumin 50%

Keyphrases

• Hypertension 100%
• Renal Injury 100%
• Autoimmunity 100%
• Lupus 42%
• Systemic Lupus Erythematosus 28%
• Lupus-prone Mice 28%
• Anti-CD20 Therapy 28%
• Tumor Necrosis Factor-α 14%
• B Cells 14%
• Mouse Model 14%
• Single-stranded DNA (ssDNA) 14%
• Patient Demographics 14%
• Disease Progression 14%
• Urinary Albumin 14%
• Autoimmune Disease 14%
• Essential Hypertension 14%
• Autoantibodies 14%
• Monocyte Chemoattractant protein-1 (MCP-1) 14%
• Renal Inflammation 14%
• Glomerulosclerosis 14%
• NZBWF1 14%
• Circulating T Cells 14%
• Hypertension Prevalence 14%
• Anti-CD20 14%
• Anti-CD20 Antibody 14%
• Autoantibody Production 14%
• Immunoglobulin G Antibodies 14%
• Urinary Neutrophil Gelatinase-associated Lipocalin (uNGAL) 14%
• Tubulointerstitial Fibrosis 14%
• Tubular Injury 14%
• Healthy Women 14%

Immunology and Microbiology

• Lipocalin 20%